Connecticut’s Coverage Mandate Signals a Shift in How Insurers Treat Biomarker Testing
Personalized Medicine Biomarkers Market Projected to Reach USD 77.37 Billion by 2034 as Treatment Selection Moves to the Center of Care
Personalized Medicine Biomarkers Market growth reflects a fundamental shift in healthcare: treatment decisions are increasingly guided by a patient’s own biology rather than population averages. According to Polaris Market Research, the industry was valued at USD 24.88 billion in 2025 and is projected to grow from USD 28.17 billion in 2026 to USD 77.37 billion by 2034, a CAGR of 13.4%. Rising chronic disease prevalence and closer collaboration between pharmaceutical and diagnostic companies are shaping this trajectory.
What Biomarkers Do
Personalized medicine biomarkers are measurable biological indicators found in blood, tissue, genes or proteins that show how a patient may respond to a disease or therapy. Predictive biomarkers indicate whether someone is likely to benefit from a particular treatment, while genomic biomarkers reveal genetic changes linked to disease susceptibility and drug sensitivity.
The workflow is straightforward. A sample is collected, tested through genomic sequencing, molecular assays or immunoassays, and compared with known biomarker profiles. The physician then selects a therapy that matches the result and may continue measuring biomarker levels during treatment to track response.
Growth Drivers
Integration into routine care. Biomarker testing is moving into everyday practice, especially in oncology, where it identifies patients who can benefit from targeted therapy. Policy is helping: Connecticut requires health insurance plans to cover biomarker tests from January 2026, part of broader efforts to close coverage gaps.
Chronic disease burden. The World Health Organization reported in October 2026 that noncommunicable diseases caused 74% of global deaths in 2023, up from 58% in 2000. Cancer remains a major contributor, with an estimated 20.6 million cases diagnosed in 2024. Because diseases such as cancer, diabetes and cardiovascular conditions vary widely between individuals, biomarkers help distinguish patient groups and guide care.
Drug development. Biomarkers are increasingly used to identify who qualifies for new treatments, design clinical trials and link medicines to the patients most likely to benefit, supporting biomarker-guided and targeted therapies.
Trends and Opportunities
Liquid biopsy is gaining ground because it uses a blood sample to track tumor-derived markers, which is valuable when tissue collection is difficult and allows clinicians to monitor molecular changes throughout treatment. Multi-biomarker panels assess several markers from a single sample, reducing the need for repeated tests and supporting decisions where one marker is not enough. Preventive care is another opportunity, as biomarkers can reveal biological changes before symptoms appear. Artificial intelligence is also accelerating discovery by finding patterns in large biological datasets and shortening evaluation time.
Companion Diagnostics in Action
FDA companion diagnostic approvals during 2026 show how closely tests and therapies are now linked. Examples include Guardant360 CDx for ESR1 mutations in breast cancer, Illumina’s TruSight Oncology Comprehensive for RET alterations in thyroid cancers, Roche’s VENTANA PTEN assay for prostate cancer, and FoundationOne CDx for MET exon 14 skipping in non-small cell lung cancer. Supporting technologies include comprehensive genomic profiling, PCR assays, immunohistochemistry, in situ hybridization and circulating tumor DNA testing.
Explore The Complete Comprehensive Report Here : https://www.polarismarketresearch.com/industry-analysis/personalized-medicine-biomarkers-market
Segment Insights
By application, treatment selection led in 2025 with a 51.8% share, as targeted medicines make it essential to confirm whether a patient carries the relevant marker, reducing the use of low-efficacy treatments. Early detection and screening is projected to grow at a 14.4% CAGR as preventive healthcare gains focus.
By indication, oncology held 35.7% because tumors differ in their biological properties and a growing library of cancer biomarkers supports more clinical tests. Diabetes is expected to grow fastest, at a 17.1% CAGR, as researchers look beyond traditional markers to understand disease formation and complication risk.
Regional Outlook
North America accounted for the largest share, at 51.3%, supported by advanced healthcare infrastructure, strong research investment, a wide network of genomic testing laboratories and recent policy moves to widen access. Asia Pacific is projected to grow fastest, at 15.8%, driven by biotechnology investment, rising government funding for precision medicine in China, wider genomic testing in Japan and expanding molecular diagnostics in India. Europe held 13.9%, while Latin America and the Middle East & Africa are expected to grow at 12.9% and 13.6% respectively.
Competitive Landscape
The industry includes diagnostics firms, biotechnology companies, pharmaceutical groups and specialist laboratories. Key participants include Abbott, AstraZeneca, BD, Roche, Foundation Medicine, Fujirebio, Labcorp, Pfizer, QIAGEN, Quest Diagnostics and Thermo Fisher Scientific. Recent activity includes QIAGEN’s August 2026 launch of QIAsymphony Connect for automated nucleic acid extraction in liquid biopsy workflows, and Roche’s April 2026 plan to acquire SAGA Diagnostics and its molecular residual disease technology.
Barriers to Overcome
Reimbursement is the main restraint. Coverage varies between insurance plans, partial reimbursement raises out-of-pocket costs, and emerging tests often need substantial clinical evidence before payers approve them. Small hospitals face budget limits that can slow adoption, and testing multiple markers increases expense.
Personalized Medicine Biomarkers Market prospects through 2034 depend on expanding insurance coverage, validating new tests with strong clinical data and widening access beyond major academic centers. Companies that combine robust companion diagnostics, liquid biopsy capability and AI-enabled discovery with strong pharmaceutical partnerships are well placed to benefit as precision treatment becomes the standard of care across oncology, diabetes and other complex diseases.
More Trending Latest Reports By Polaris Market Research:
Drinking Water Adsorbents Market
Warehouse Management System Market
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Jogos
- Gardening
- Health
- Início
- Literature
- Music
- Networking
- Outro
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness